“The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics”
- 1 August 2021
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 904, 174169
Abstract
No abstract availableKeywords
Funding Information
- Central University of Punjab
This publication has 34 references indexed in Scilit:
- First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusBMC Pharmacology and Toxicology, 2013
- Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2013
- Simultaneous oral therapeutic and intravenous 14C‐microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozinBritish Journal of Clinical Pharmacology, 2013
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011
- SGLT2 inhibition — a novel strategy for diabetes treatmentNature Reviews Drug Discovery, 2010
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implicationsDiabetic Medicine, 2010
- Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent ModelsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Active sugar transport in health and diseaseJournal of Internal Medicine, 2007
- The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant functionJournal of Parenteral and Enteral Nutrition, 2004
- The sodium/glucose cotransport family SLC5Pflügers Archiv - European Journal of Physiology, 2004